300238 冠昊生物
已收盘 12-20 15:00:00
资讯
新帖
简况
冠昊生物(300238)11月29日股东户数2.88万户，较上期减少0.49%
证券之星 · 12-05
冠昊生物(300238)11月29日股东户数2.88万户，较上期减少0.49%
冠昊生物最新公告：控股股东所持公司部分股份将被司法拍卖
证券之星 · 11-29
冠昊生物最新公告：控股股东所持公司部分股份将被司法拍卖
冠昊生物(300238)11月20日股东户数2.9万户，较上期减少5.55%
证券之星 · 11-26
冠昊生物(300238)11月20日股东户数2.9万户，较上期减少5.55%
冠昊生物(300238)11月8日股东户数3.07万户，较上期增加0.61%
证券之星 · 11-13
冠昊生物(300238)11月8日股东户数3.07万户，较上期增加0.61%
冠昊生物：相关事项的进展情况，敬请查阅公司近日在指定信息披露网站已披露的公告
证券之星 · 11-07
冠昊生物：相关事项的进展情况，敬请查阅公司近日在指定信息披露网站已披露的公告
冠昊生物（300238）2024年三季报简析：净利润减32.55%，盈利能力上升
证券之星 · 10-30
冠昊生物（300238）2024年三季报简析：净利润减32.55%，盈利能力上升
A股脑机接口概念尾盘异动，创新医疗直线拉升涨停，三博脑科、诚益通、爱朋医疗、冠昊生物等跟涨。
美港电讯 · 10-29
A股脑机接口概念尾盘异动，创新医疗直线拉升涨停，三博脑科、诚益通、爱朋医疗、冠昊生物等跟涨。
图解冠昊生物三季报：第三季度单季净利润同比减26.98%
证券之星 · 10-29
图解冠昊生物三季报：第三季度单季净利润同比减26.98%
冠昊生物(300238.SZ)发布前三季度业绩，净利润2783.63万元，下降32.55%
智通财经 · 10-28
冠昊生物(300238.SZ)发布前三季度业绩，净利润2783.63万元，下降32.55%
冠昊生物（300238）10月22日主力资金净买入4555.47万元
证券之星 · 10-22
冠昊生物（300238）10月22日主力资金净买入4555.47万元
冠昊生物(300238)10月10日股东户数3.07万户，较上期减少7.63%
证券之星 · 10-15
冠昊生物(300238)10月10日股东户数3.07万户，较上期减少7.63%
冠昊生物(300238)9月30日股东户数3.33万户，较上期增加3.53%
证券之星 · 10-09
冠昊生物(300238)9月30日股东户数3.33万户，较上期增加3.53%
冠昊生物（300238）10月9日主力资金净卖出4210.60万元
证券之星 · 10-09
冠昊生物（300238）10月9日主力资金净卖出4210.60万元
冠昊生物（300238）9月26日主力资金净卖出207.29万元
证券之星 · 09-26
冠昊生物（300238）9月26日主力资金净卖出207.29万元
冠昊生物（300238）9月20日主力资金净卖出1121.64万元
证券之星 · 09-20
冠昊生物（300238）9月20日主力资金净卖出1121.64万元
A股医疗器械板块盘初走低，英科医疗、阳普医疗双双跌停，冠昊生物、中红医疗、华大智造、利德曼等跌幅居前。
美港电讯 · 09-18
A股医疗器械板块盘初走低，英科医疗、阳普医疗双双跌停，冠昊生物、中红医疗、华大智造、利德曼等跌幅居前。
冠昊生物：公司已获得注册证及注册中的产品情况详情请您参见公司定期报告
证券之星 · 09-10
冠昊生物：公司已获得注册证及注册中的产品情况详情请您参见公司定期报告
A股收评：创业板指涨0.06% 免疫治疗概念走强
美港电讯 · 09-09
A股收评：创业板指涨0.06% 免疫治疗概念走强
外商独资医院试点，堪比新能车引进特斯拉？医药股逆势爆发
格隆汇 · 09-09
外商独资医院试点，堪比新能车引进特斯拉？医药股逆势爆发
A股午评：沪指跌0.92% 免疫治疗概念掀涨停潮
美港电讯 · 09-09
A股午评：沪指跌0.92% 免疫治疗概念掀涨停潮
暂无数据
公司概况
公司名称：
冠昊生物科技股份有限公司
所属行业：
专用设备制造业
上市日期：
2011-07-06
主营业务：
冠昊生物科技股份有限公司是一家从事再生医学材料及再生型医用植入器械研发、生产及销售的高科技企业。公司主要从事研究、开发、生产:Ⅱ类、Ⅲ类:6846植入材料和人工器官,6846医用卫生材料及敷料;销售自产产品及提供服务;三类、二类:植入材料和人工器官,医用卫生材料及敷料的批发、零售。公司的技术研究和产品开发紧跟国家发展方向，目前公司参与了两项“十三五”国家重点研发计划，均是围绕组织修复与可再生材料进行技术创新和新产品开发。
发行价格：
18.20
{"stockData":{"symbol":"300238","market":"SZ","secType":"STK","nameCN":"冠昊生物","latestPrice":13.81,"timestamp":1734678189000,"preClose":14.15,"halted":0,"volume":9940700,"delay":0,"floatShares":265000000,"shares":265000000,"eps":0.0663,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.34,"latestTime":"12-20 15:00:00","open":14.1,"high":14.13,"low":13.76,"amount":138000000,"amplitude":0.0261,"askPrice":13.82,"askSize":194,"bidPrice":13.81,"bidSize":114,"shortable":0,"etf":0,"ttmEps":0.0663,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":14.15,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":15.57,"lowLimit":12.74,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":265155701,"pbRate":6.87,"roa":"--","roe":"5.22%","epsLYR":0.12,"committee":0.422259,"marketValue":3662000000,"floatMarketCap":3662000000,"peRate":208.295635,"changeRate":-0.024,"turnoverRate":0.0375,"status":1},"requestUrl":"/m/hq/s/300238/tweets","defaultTab":"tweets","newsList":[{"id":"2489448784","title":"冠昊生物(300238)11月29日股东户数2.88万户，较上期减少0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489448784","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489448784?lang=zh_cn&edition=full","pubTime":"2024-12-05 17:05","pubTimestamp":1733389540,"startTime":"0","endTime":"0","summary":"证券之星消息，近日冠昊生物披露，截至2024年11月29日公司股东户数为2.88万户，较11月20日减少141.0户，减幅为0.49%。在医疗器械行业个股中，冠昊生物股东户数高于行业平均水平，截至11月29日，医疗器械行业平均股东户数为2.05万户。从股价来看，2024年11月20日至2024年11月29日，冠昊生物区间跌幅为0.45%，在此期间股东户数减少141.0户，减幅为0.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120500028213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0251","BK0042","BK0086","300238","BK0046"],"gpt_icon":0},{"id":"2487253682","title":"冠昊生物最新公告：控股股东所持公司部分股份将被司法拍卖","url":"https://stock-news.laohu8.com/highlight/detail?id=2487253682","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487253682?lang=zh_cn&edition=full","pubTime":"2024-11-29 17:29","pubTimestamp":1732872585,"startTime":"0","endTime":"0","summary":"冠昊生物公告称，公司控股股东广东知光所持有的公司股份104,822股和16,980,000股拟将分别被司法拍卖，合计占其所持公司股份的49.67%，占公司总股本的6.44%。本次司法拍卖事项尚处于公示阶段，拍卖结果存在不确定性。公司将密切关注后续进展情况，及时履行信息披露义务。若此次公示将被拍卖的17,084,822股股份最终均完成司法拍卖，广东知光及其一致行动人合计持有公司股份将可能由70,411,088股减少至53,326,266股，占公司总股本的比例将由26.55%降至20.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900028326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238","BK0077","BK0042","BK0086","BK0046","BK0251"],"gpt_icon":0},{"id":"2486026378","title":"冠昊生物(300238)11月20日股东户数2.9万户，较上期减少5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486026378","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486026378?lang=zh_cn&edition=full","pubTime":"2024-11-26 17:04","pubTimestamp":1732611856,"startTime":"0","endTime":"0","summary":"证券之星消息，近日冠昊生物披露，截至2024年11月20日公司股东户数为2.9万户，较11月8日减少1701.0户，减幅为5.55%。在医疗器械行业个股中，冠昊生物股东户数高于行业平均水平，截至11月20日，医疗器械行业平均股东户数为2.05万户。从股价来看，2024年11月8日至2024年11月20日，冠昊生物区间跌幅为8.3%，在此期间股东户数减少1701.0户，减幅为5.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112600028638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0251","BK0046","BK0077","300238","BK0086"],"gpt_icon":0},{"id":"2483078441","title":"冠昊生物(300238)11月8日股东户数3.07万户，较上期增加0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483078441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483078441?lang=zh_cn&edition=full","pubTime":"2024-11-13 17:03","pubTimestamp":1731488623,"startTime":"0","endTime":"0","summary":"证券之星消息，近日冠昊生物披露，截至2024年11月8日公司股东户数为3.07万户，较10月31日增加185.0户，增幅为0.61%。在医疗器械行业个股中，冠昊生物股东户数高于行业平均水平，截至11月8日，医疗器械行业平均股东户数为2.06万户。从股价来看，2024年10月31日至2024年11月8日，冠昊生物区间涨幅为11.36%，在此期间股东户数增加185.0户，增幅为0.61%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300028855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0251","BK0042","BK0086","300238","BK0046"],"gpt_icon":0},{"id":"2481973899","title":"冠昊生物：相关事项的进展情况，敬请查阅公司近日在指定信息披露网站已披露的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2481973899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481973899?lang=zh_cn&edition=full","pubTime":"2024-11-07 18:00","pubTimestamp":1730973652,"startTime":"0","endTime":"0","summary":"证券之星消息，冠昊生物(300238)11月07日在投资者关系平台上答复投资者关心的问题。投资者：请问公司的法人股拍卖有结果了吗？冠昊生物董秘：尊敬的投资者您好！相关事项的进展情况，敬请查阅公司近日在指定信息披露网站已披露的公告。感谢您的关注与支持！投资者：贵公司你好!我想问一下公司对脑机接口方面有研发投入吗谢谢冠昊生物董秘：尊敬的投资者您好！公司暂无相关研究。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700029204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0042","300238","BK0086","BK0251","BK0046"],"gpt_icon":0},{"id":"2479615602","title":"冠昊生物（300238）2024年三季报简析：净利润减32.55%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479615602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479615602?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:28","pubTimestamp":1730240915,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期冠昊生物发布2024年三季报。截至本报告期末，公司营业总收入2.78亿元，同比下降9.97%，归母净利润2783.63万元，同比下降32.55%。按单季度数据看，第三季度营业总收入8843.73万元，同比下降9.88%，第三季度归母净利润768.79万元，同比下降26.98%。本报告期冠昊生物盈利能力上升，毛利率同比增幅2.65%，净利率同比增幅22.93%。去年的净利率为5.21%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000006547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238"],"gpt_icon":0},{"id":"2479441042","title":"A股脑机接口概念尾盘异动，创新医疗直线拉升涨停，三博脑科、诚益通、爱朋医疗、冠昊生物等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2479441042","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479441042?lang=zh_cn&edition=full","pubTime":"2024-10-29 14:35","pubTimestamp":1730183728,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002173","BK0251","BK0114","BK0096","BK0077","159982","BK0236","BK0042","300430","BK0046","399300","BK0086","300753","300238","BK0130","BK0225","301293","BK0028"],"gpt_icon":0},{"id":"2479437923","title":"图解冠昊生物三季报：第三季度单季净利润同比减26.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479437923","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479437923?lang=zh_cn&edition=full","pubTime":"2024-10-29 01:29","pubTimestamp":1730136551,"startTime":"0","endTime":"0","summary":"证券之星消息，冠昊生物2024年三季报显示，公司主营收入2.78亿元，同比下降9.97%；归母净利润2783.63万元，同比下降32.55%；扣非净利润2023.5万元，同比下降46.88%；其中2024年第三季度，公司单季度主营收入8843.73万元，同比下降9.88%；单季度归母净利润768.79万元，同比下降26.98%；单季度扣非净利润131.19万元，同比下降87.55%；负债率35.5%，投资收益80.57万元，财务费用64.74万元，毛利率78.64%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900000900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238"],"gpt_icon":0},{"id":"2479436614","title":"冠昊生物(300238.SZ)发布前三季度业绩，净利润2783.63万元，下降32.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479436614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479436614?lang=zh_cn&edition=full","pubTime":"2024-10-28 23:59","pubTimestamp":1730131195,"startTime":"0","endTime":"0","summary":"智通财经APP讯，冠昊生物(300238.SZ)发布2024年三季度报告，该公司前三季度营业收入为2.78亿元，同比减少9.97%。归属于上市公司股东的净利润为2783.63万元，同比减少32.55%。归属于上市公司股东的扣除非经常性损益的净利润为2023.5万元，同比减少46.88%。基本每股收益为0.1元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300238"],"gpt_icon":0},{"id":"2477803530","title":"冠昊生物（300238）10月22日主力资金净买入4555.47万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477803530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477803530?lang=zh_cn&edition=full","pubTime":"2024-10-22 15:20","pubTimestamp":1729581650,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月22日收盘，冠昊生物报收于13.47元，上涨5.65%，换手率8.66%，成交量22.96万手，成交额3.02亿元。10月22日的资金流向数据方面，主力资金净流入4555.47万元，占总成交额15.08%，游资资金净流入292.64万元，占总成交额0.97%，散户资金净流出4848.11万元，占总成交额16.04%。冠昊生物主营业务：生产和销售医疗器械、药品及提供细胞技术服务等。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200018169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0086","BK0077","BK0251","300238","BK0046"],"gpt_icon":0},{"id":"2475523961","title":"冠昊生物(300238)10月10日股东户数3.07万户，较上期减少7.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475523961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475523961?lang=zh_cn&edition=full","pubTime":"2024-10-15 17:02","pubTimestamp":1728982960,"startTime":"0","endTime":"0","summary":"证券之星消息，近日冠昊生物披露，截至2024年10月10日公司股东户数为3.07万户，较9月30日减少2539.0户，减幅为7.63%。在医疗器械行业个股中，冠昊生物股东户数高于行业平均水平，截至10月10日，医疗器械行业平均股东户数为2.01万户。从股价来看，2024年9月30日至2024年10月10日，冠昊生物区间跌幅为2.0%，在此期间股东户数减少2539.0户，减幅为7.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101500027695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238","BK0077","BK0046","BK0086","BK0251","BK0042"],"gpt_icon":0},{"id":"2474176602","title":"冠昊生物(300238)9月30日股东户数3.33万户，较上期增加3.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474176602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474176602?lang=zh_cn&edition=full","pubTime":"2024-10-09 18:15","pubTimestamp":1728468950,"startTime":"0","endTime":"0","summary":"证券之星消息，近日冠昊生物披露，截至2024年9月30日公司股东户数为3.33万户，较8月20日增加1136.0户，增幅为3.53%。在医疗器械行业个股中，冠昊生物股东户数高于行业平均水平，截至9月30日，医疗器械行业平均股东户数为2.01万户。从股价来看，2024年8月20日至2024年9月30日，冠昊生物区间涨幅为45.57%，在此期间股东户数增加1136.0户，增幅为3.53%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100900033452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0086","BK0077","BK0251","300238","BK0046"],"gpt_icon":0},{"id":"2474292728","title":"冠昊生物（300238）10月9日主力资金净卖出4210.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474292728","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474292728?lang=zh_cn&edition=full","pubTime":"2024-10-09 15:46","pubTimestamp":1728459965,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月9日收盘，冠昊生物报收于12.65元，下跌16.78%，换手率11.68%，成交量30.97万手，成交额4.23亿元。10月9日的资金流向数据方面，主力资金净流出4210.6万元，占总成交额9.96%，游资资金净流出1566.09万元，占总成交额3.71%，散户资金净流入5776.68万元，占总成交额13.67%。冠昊生物主营业务：生产和销售医疗器械、药品及提供细胞技术服务等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100900023431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0077","BK0046","BK0042","BK0086","300238"],"gpt_icon":0},{"id":"2470270716","title":"冠昊生物（300238）9月26日主力资金净卖出207.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470270716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470270716?lang=zh_cn&edition=full","pubTime":"2024-09-26 15:21","pubTimestamp":1727335272,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月26日收盘，冠昊生物报收于10.66元，上涨6.49%，换手率12.68%，成交量33.61万手，成交额3.52亿元。9月26日的资金流向数据方面，主力资金净流出207.29万元，占总成交额0.59%，游资资金净流入2657.4万元，占总成交额7.55%，散户资金净流出2450.11万元，占总成交额6.96%。冠昊生物主营业务：生产和销售医疗器械、药品及提供细胞技术服务等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092600017113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0042","BK0086","BK0046","300238","BK0251"],"gpt_icon":0},{"id":"2468945016","title":"冠昊生物（300238）9月20日主力资金净卖出1121.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468945016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468945016?lang=zh_cn&edition=full","pubTime":"2024-09-20 15:23","pubTimestamp":1726817007,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月20日收盘，冠昊生物报收于9.72元，下跌2.51%，换手率5.29%，成交量14.01万手，成交额1.37亿元。9月20日的资金流向数据方面，主力资金净流出1121.64万元，占总成交额8.19%，游资资金净流出526.5万元，占总成交额3.85%，散户资金净流入1648.13万元，占总成交额12.04%。冠昊生物主营业务：生产和销售医疗器械、药品及提供细胞技术服务等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092000016912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","BK0086","300238","BK0251","BK0042"],"gpt_icon":0},{"id":"2468141345","title":"A股医疗器械板块盘初走低，英科医疗、阳普医疗双双跌停，冠昊生物、中红医疗、华大智造、利德曼等跌幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2468141345","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468141345?lang=zh_cn&edition=full","pubTime":"2024-09-18 09:34","pubTimestamp":1726623267,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0146","BK1100","09996","BK0028","BK0251","09997","BK0077","BK0046","BK1222","BK0220","300981","159883","BK0042","BK0086","300030","300289","688114","BK1583","159982","399300","BK1574","BK0239","300677","300238"],"gpt_icon":0},{"id":"2466489725","title":"冠昊生物：公司已获得注册证及注册中的产品情况详情请您参见公司定期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2466489725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466489725?lang=zh_cn&edition=full","pubTime":"2024-09-10 17:03","pubTimestamp":1725959015,"startTime":"0","endTime":"0","summary":"证券之星消息，冠昊生物(300238)09月10日在投资者关系平台上答复投资者关心的问题。投资者：公司有正在申请的新产品批文吗？具体进度如何？谢谢！冠昊生物董秘：尊敬的投资者您好！公司已获得注册证及注册中的产品情况详情请您参见公司定期报告。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091000027333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0077","BK0042","BK0046","BK0086","300238"],"gpt_icon":0},{"id":"2466213147","title":"A股收评：创业板指涨0.06% 免疫治疗概念走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2466213147","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466213147?lang=zh_cn&edition=full","pubTime":"2024-09-09 15:05","pubTimestamp":1725865511,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300238","161032","399300","BK0077","BK0042","000819.SH","399001","BK1209","300030","399006","BK0251","159982","BK0046","BK0086","BK0146","BK0028","165316","159871","09906"],"gpt_icon":0},{"id":"2466138497","title":"外商独资医院试点，堪比新能车引进特斯拉？医药股逆势爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2466138497","media":"格隆汇","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466138497?lang=zh_cn&edition=full","pubTime":"2024-09-09 13:40","pubTimestamp":1725860453,"startTime":"0","endTime":"0","summary":"机构：有望迎来整体反转","market":"hk","thumbnail":"https://img3.gelonghui.com/94749-756c6682-470e-41b8-9006-d9c6b71633e8.jpg?guru_height=826&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/94749-756c6682-470e-41b8-9006-d9c6b71633e8.jpg?guru_height=826&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1019901","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["IE00BWXC8680.SGD","BK0188","LU2602419157.SGD","BK4555","BK0042","000566","LU0823414478.USD","BK4550","LU2756315318.SGD","LU0053666078.USD","LU0689472784.USD","300030","LU0234572021.USD","BK4551","BK4533","BK0077","LU1720051017.SGD","BK0239","LU0348723411.USD","002172","LU0820561818.USD","LU0097036916.USD","TSLL","LU1548497426.USD","LU2213496289.HKD","LU1861220033.SGD","BK4534","BK4099","603222","BK1515","BK4548","BK4511","LU2357305700.SGD","LU2063271972.USD","09939","BK0236","LU1629891620.HKD","BK0060","BK1161","LU0943347566.SGD","LU2756315664.SGD","LU0820561909.HKD","BK0181","BK0086","LU0316494557.USD","300238","000516","LU1861559042.SGD","LU0823411888.USD"],"gpt_icon":1},{"id":"2466186732","title":"A股午评：沪指跌0.92% 免疫治疗概念掀涨停潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2466186732","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466186732?lang=zh_cn&edition=full","pubTime":"2024-09-09 11:33","pubTimestamp":1725852810,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0146","000819.SH","399001","BK0046","BK0086","BK0077","BK1132","BK0042","159982","BK0028","165316","300030","BK0251","161032","09906","BK1209","08496","399006","300238","159871","399300"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-07-06","address":"广东省广州市黄埔区玉岩路12号","stockEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.4208},{"period":"6month","weight":0.4691},{"period":"1year","weight":0.0117},{"period":"ytd","weight":0.0184}],"companyName":"冠昊生物科技股份有限公司","boardCode":"AI0035","perCapita":"8953股","boardName":"专用设备制造业","registeredCapital":"26515万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":" 冠昊生物科技股份有限公司是一家从事再生医学材料及再生型医用植入器械研发、生产及销售的高科技企业。公司主要从事研究、开发、生产:Ⅱ类、Ⅲ类:6846植入材料和人工器官,6846医用卫生材料及敷料;销售自产产品及提供服务;三类、二类:植入材料和人工器官,医用卫生材料及敷料的批发、零售。公司的技术研究和产品开发紧跟国家发展方向，目前公司参与了两项“十三五”国家重点研发计划，均是围绕组织修复与可再生材料进行技术创新和新产品开发。","serverTime":1734777643107,"listedPrice":18.2,"stockholders":"29611人(较上一季度增加2.75%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"冠昊生物(300238)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供冠昊生物(300238)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"冠昊生物,300238,冠昊生物股票,冠昊生物股票老虎,冠昊生物股票老虎国际,冠昊生物行情,冠昊生物股票行情,冠昊生物股价,冠昊生物股市,冠昊生物股票价格,冠昊生物股票交易,冠昊生物股票购买,冠昊生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"冠昊生物(300238)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供冠昊生物(300238)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}